论文部分内容阅读
目的 观察Graves病患者131I治疗后甲状腺重量和功能变化 ,探讨最佳131I治疗剂量。方法 10 3例Graves病患者131I治疗前后均进行核素显像和B超测量甲状腺重量及甲状腺功能测定。结果 甲状腺重量的变化 :90例患者治疗后 6～ 7个月复查甲状腺重量 ,核素显像由 (5 1.5±2 3 .4)g至 (2 7.0± 13 .9) g ;超声测量法由 (47.2± 2 3.7) g至 (2 0 .6± 8.4)g。131I治疗后甲状腺重量下降量与治疗前重量呈正相关 (超声测量法 ) (r =0 .49,P <0 .0 1)。临床随访 (31.0± 13 .4)个月 ,治愈 73例 (70 .9% ) ,甲状腺功能正常 5 8例 (5 6 .3 % ) ;晚发甲减 15例 (其中亚临床甲减 6例 ) (14.6 % ) ;未愈30例 (2 9.1% )。结论 Graves病患者131I治疗后能显著减少甲状腺重量 ,甲状腺重量下降率与治疗前甲状腺重量呈正相关
Objective To observe the changes of thyroid weight and function after treatment of 131I in patients with Graves disease and to explore the best 131I treatment dose. Methods Thirteen cases of Graves’ disease were treated with radionuclide imaging and thyroid function measurement before and after 131I treatment. Results Thyroid weight changes: The thyroid weight was reviewed in 90 patients 6 to 7 months after treatment, and the radionuclide imaging was (5 1.5 ± 23.4) g to (2 7.0 ± 13.9) g. The ultrasound measurement consisted of (47.2 ± 2 3.7) g to (20.6 ± 8.4) g. Thyroid weight loss after 131I treatment was positively correlated with pretreatment weight (echocardiography) (r = 0.49, P <0.01). Clinical follow-up (31.0 ± 13.4) months, cured 73 cases (70.9%), thyroid normal 58 cases (56.3%); late hypothyroidism in 15 cases (including 6 cases of subclinical hypothyroidism ) (14.6%); healed 30 cases (21.9%). Conclusions 131I treatment in patients with Graves disease can significantly reduce thyroid weight, the rate of thyroid weight loss and thyroid weight before treatment was positively correlated